-
Mashup Score: 1
At the 2024 UCSF-UCLA PSMA Conference, Michael Morris reviews the VISION and TheraP trials, underscoring their significance in advancing PSMA PET imaging and radioligand therapy for prostate cancer, particularly highlighting lutetium PSMA-617’s efficacy in improving survival and quality of life as shown in the VISION trial. Dr. Morris stresses the importance of further research to refine patient…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1
At the 2024 UCSF-UCLA PSMA Conference, Michael Morris reviews the VISION and TheraP trials, underscoring their significance in advancing PSMA PET imaging and radioligand therapy for prostate cancer, particularly highlighting lutetium PSMA-617’s efficacy in improving survival and quality of life as shown in the VISION trial. Dr. Morris stresses the importance of further research to refine patient…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Dive into the latest from the 2024 @UCSF @UCLA @PCFnews @PSMAconference! @morr316 unpacks the #VISION and #TheraP trials, spotlighting lutetium PSMA-617's impact on #prostatecancer survival and quality of life > https://t.co/6FVRW2auot https://t.co/kEj7fAipcx